Does the use of cysteine-rich whey protein supplements (Inmunocal®) improve the health well-being of COVID-19 patients? A qualitative study

Author:

Cañari Betsy1ORCID,Moya-Salazar Jeel12ORCID,Bussalleu Daniela3ORCID,Contreras-Pulache Hans1ORCID

Affiliation:

1. South American Center for Research in Education and Public Health, Universidad Norbert Wiener, Lima, PERU

2. Hospital Nacional Docente Madre Niño San Bartolomé, Lima, PERU

3. Public Minister, Lima, PERU

Abstract

<b>Introduction:</b> In the context of SARS-CoV-2 infection, it has been proposed that oxidative stress may contribute to the management of COVID-19 severity. The impact on the well-being of patients with COVID-19 using cysteine-providing supplements has not yet been evaluated and there is a need to understand the benefits and limitations they may offer.<br /> <b>Aim:</b> The aim of this study is to understand the experiences of improved well-being with cysteine-rich whey protein supplementation (Immunocal®) in patients with COVID-19.<br /> <b>Methods:</b> A qualitative study was conducted by conducting semi-structured interviews with four participants taking Immunocal® while they had COVID-19. Participants were randomly recruited through internet networking. Ethical approval was obtained from the University ethics committee. Participants were informed of the study objectives two days in advance and consent was obtained before interviews began. We used the 16-item “Use of Immunocal supplement for COVID-19” (USIC-19) questionnaire to inquire about COVID-19 behavior (time of illness, symptoms, and severity of illness) and the experience of using the supplement during illness. Confidentiality was maintained throughout this study.<br /> <b>Results:</b> All participants presented mild discomfort such as headache, weakness, and tiredness when they had COVID-19 impacting most of them emotionally. The use of Immunocal® produced a partial improvement in all patients as only two continued to experience fatigue. Immunocal® improved the mood (50%) and physical health of the participants. In addition, participants reported that the supplement was recommended and dosed primarily by a consultant and that they did not feel hesitant to use it because of previous experiences of friends and family. The daily dosage of half of the participants was two sachets and all felt the need to consume the supplement which resulted in daily use.<br /> <b>Conclusion:</b> Following the daily dosage indications of the consultants, the participants who have consumed Inmunocal® have presented a partial improvement of the symptoms related to COVID-19, however, they feel the need to consume the supplement daily to improve their quality of life.

Publisher

Modestum Ltd

Subject

General Medicine

Reference31 articles.

1. World Health Organization. Monthly operational update on COVID-19-May 2022. Available at: https://www.who.int/publications/m/item/monthly-operational-update-on-covid-19---may-2022 (Accessed 10 July 2022).

2. Nie Z, Sun T, Zhao F. Safety and efficacy of antiviral drugs for the treatment of COVID-19: A systematic review. Infect Drug Resist. 2022;(15):4457-66. https://doi.org/10.2147/IDR.S362946 PMid:35983302 PMCid:PMC9381013

3. García-Albéniz X, del Amo J, Morales- Asencio J, Hernan M. Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. Eur J Epidemiol. 2022;37(8):789-96. https://doi.org/10.1007/s10654-022-00891-4 PMid:35943669 PMCid:PMC9360718

4. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: A systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022;399(10334):1513-36.

5. Seguro Social del Perú [Social Security of Peru]. Guía de práctica clínica para el manejo de COVID-19: Guía en versión extensa. Versión 2 [Clinical practice guide for the management of COVID-19: Guide in long version. Version 2]. Lima: EsSalud; 2021. Available at: http://www.essalud.gob.pe/ietsi/pdfs/guias/GPC_COVID19_In_extenso_V2_Julio2021.pdf (Accessed 10 July 2022).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3